DRDATSONS

Dr. Datson's Labs Limited has informed the Exchange regarding the Change in Corporate/ Admin Office of the Company:- From Plot No 34, Postal Colony, Chembur, Mumbai 400071, India To Dr. Datsons House, Plot No W-91(D) MIDC Taloja 410208, Dist -Raigad, State- Maharashtra India w.e.f. August 01, 2014.

Dr. Datson's Labs Limited has informed the Exchange that the company has successfully completed its obligations towards the FCCB Bond Holders for 40 Million USD. There is no Unpaid Debt by the company towards Bondholders as on July 17, 2014.The Management express its gratitude to shareholders for their unflinching support to the company.

Dr. Datson's Labs Limited has submitted to the Exchange a copy of the Postal Ballot Notice pursuant to Section 110 of the Companies Act, 2013 ('the "ACT") read with the Companies (Management and Administration) Rules, 2014.

Dr. Datson's Labs Limited has submitted to the Exchange vide letter dated July 10, 2014 a copy of disclosure pursuant to Regulation 13(1) and 13(6) of the SEBI (Prohibition of Insider Trading) Regulations, 1992.

Leman Diversified Fund has submitted to the Exchange vide letter dated July 08, 2014 a copy of disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. along with a copy of disclosure pursuant to Regulation 13(1) and 13(6) of the SEBI (Prohibition of Insider Trading) Regulations, 1992.

Davos International Fund has submitted to the Exchange copy of disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 along with a copy of disclosure pursuant to Regulation 13(1) and 13(6) of the SEBI (Prohibition of Insider Trading) Regulations, 1992 dated July 04, 2014.

Dr. Datson's Labs Limited has submitted to the Exchange vide letter dated July 05, 2014 a copy of disclosure pursuant to Regulation 13(1) and 13(6) of the SEBI (Prohibition of Insider Trading) Regulations, 1992.

Dr. Datson's Labs Limited has informed the Exchange that the Board of Directors of the Company in its meeting held on July 5, 2014 has : Approved and finalized the Notice of Postal Ballot under Section 110 of the Companies Act, 2013 for the following matter: 1) To Increase Authorized Capital of the Company from Rs. 80,00,00,000/-( Rupees Eighty Crore Only) divided in to 8,00,00,000(Eight Crores Only) equity shares of Rs.10/-( Rupees Ten only) to Rs. 110,00,00,000/-( Rupees One Hundred Ten Crores Only) divided in to 11,00,00,000(Eleven Crores Only) equity shares of Rs.10/-( Rupees Ten only) and

Dr. Datson's Labs Limited has submitted to the Exchange vide letter dated July 01, 2014 a copy of disclosure pursuant to Regulation 13(1) and 13(6) of the SEBI (Prohibition of Insider Trading) Regulations, 1992.

Dr. Datson's Labs Limited has informed the Exchange that the Company received International Star Award for Quality to be conferred upon the company at the ISAQ Convention.

Davos International Fund has submitted to the Exchange vide letter dated June 30, 2014 a copy of disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 along with a copy of disclosure pursuant to Regulation 13(1) and 13(6) of the SEBI (Prohibition of Insider Trading) Regulations, 1992.

Dr. Datson's Labs Limited has informed the Exchange regarding a Outcome of Board Meeting of the Company held on June 27, 2014.

Stream Value Fund has submitted to the Exchange vide letter dated June 17, 2014 a copy of disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 along with a copy of Disclosure under Regulation 13(1) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Dr. Datson's Labs Limited has submitted to the Exchange vide letter dated June 18, 2014 a copy of disclosure pursuant to Regulation 13(4), 13(4A) and 13(6) of the SEBI (Prohibition of Insider Trading) Regulations, 1992.

Dr. Datson's Labs Limited has submitted to the Exchange vide letter dated June 18, 2014 a copy of disclosure pursuant to Regulation 13(1) and 13(6) of the SEBI (Prohibition of Insider Trading) Regulations, 1992.

Dr. Datson's Labs Limited has informed the Exchange, vide letter dated June 16, 2014 regarding the results of the Postal Ballot conducted by the Company and as declared by the Vice Chairman based on the Scrutinizer's Report.

Dr. Datson's Labs Limited has informed the Exchange regarding disclosures under Regulation 13 (3) and (6)] of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Dr. Datson's Labs Limited has informed the Exchange regarding the outcome of board meeting of the Company held on June 02, 2014.

Dr. Datson's Labs Limitedhas submitted to the Exchange vide letter dated May 30, 2014 a copy of disclosure pursuant to Regulation 13(1) and 13(6) of the SEBI (Prohibition of Insider Trading) Regulations, 1992.

Dr. Datson's Labs Limited has submitted to the exchange the standalone & consolidated financial results for the period ended 31-Mar-2014.

Religare Finvest Limited has submitted to the Exchange, vide letter dated May 29, 2014 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Davos International Fund has submitted to the Exchange, vide letter dated May 28, 2014 a copy of disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Sparrow Asia Diversified Opportunities Fund has submitted to the Exchange, vide letter dated May 29, 2014 a copy of disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Leman Diversified Fund has submitted to the Exchange, vide letter dated May 29, 2014 a copy of disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Dr. Datson's Labs Limitedhas submitted to the Exchange vide letter dated May 29, 2014 a copy of disclosure pursuant to Regulation 13(1) and 13(6) of the SEBI (Prohibition of Insider Trading) Regulations, 1992.

Dr. Datson's Labs Limited has submitted to the Exchange vide letter dated May 23, 2014 a copy of disclosure pursuant to Regulation 13(1) and 13(6) of the SEBI (Prohibition of Insider Trading) Regulations, 1992.

Stream Value Fund has submitted to the Exchange vide letter dated May 22, 2014 a copy of disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 along with a copy of disclosure pursuant to Regulation 13(1) and 13(6) of the SEBI (Prohibition of Insider Trading) Regulations, 1992.

Dr. Datson's Labs Limited has informed the Exchange that in accordance with the provisions of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 1992, the trading window of the Company will remain closed from May 19, 2014 to May 31, 2014 for the purpose of consider and approve the Audited Financial Results for the financial year ended March 31, 2014.

Leman Diversified Fund has submitted to the Exchange vide letter dated May 02, 2014 a copy of disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 along with a copy of Disclosure under Regulation 13(1) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Sparrow asia Diversified Opportunities Fund has submitted to the Exchange vide letter dated April 29, 2014 a copy of disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 along with a copy of Disclosure under Regulation 13(1) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Dr. Datson's Labs Limited has informed the Exchange that Mires B.V ( Proposed Acquirer ) completed the valuation of the two plants of the company situated at Mahad and Pune. The Total Fair Valuation of the Company as stood at Rs 350 Crores out which valuation of the fixed assets of the company stood at Rs. 270 Crores. The Detailed term sheet for process of proposed Acquisition will be received by the company shortly.The Company undertakes to take all necessary steps for the Benefit of the stakeholders of the company.

Dr. Datson's Labs Limited has informed the Exchange regarding a outcome of Board Meeting held on May 15, 2014.

Dr. Datson's Labs Limited has submitted to the Exchange a copy of the postal ballot notice of the Company.

Dr. Datson's Labs Limited has submitted to the Exchange a copy of the Calendar of Events for the Postal Ballot process of the Company.

Leman Diversified Fund has submitted to the Exchange vide letter dated May 08, 2014 a copy of disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 along with a copy of Disclosure under Regulation 13(1) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Dr. Datson's Labs Limited has submitted to the Exchange the outcome of Meeting of the Board of Directors of the Company held on May 10, 2014.

Dr. Datson's Labs Limited has submitted to the Exchange vide letter dated May 09, 2014 a copy of Disclosure under Regulation 13(1) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Davos International Fund has submitted to the Exchange vide letter dated May 07, 2014 a copy of disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 along with disclosure under regulation 13(1) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Dr. Datson's Labs Limited has submitted to the Exchange vide letter dated May 02, 2014 a copy of Disclosure under Regulation 13(1) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Dr. Datson's Labs Limited has informed the Exchange that "the company has received Letter of interest between Mires B.V a European based Pharma Company ( Proposed Acquirer ) and Dr. Datsons Labs Limited ( Target Company ) Summarize their mutual interest in the Acquirer buying the Target Company. The Acquirer Proposed the Enterprise Valuation of the target company is decided post Due Diligence. The Acquirer proposed to buy Majority stake in the target company and The Company undertakes to take all necessary steps for the Benefit of the stakeholders of the company".

Dr. Datson's Labs Limited has submitted to the Exchange vide letter dated April 18, 2014 a copy of Disclosure under Regulation 13(1) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Stream Value Fund has submitted to the Exchange vide letter dated April 18, 2014 a copy of disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 along with disclosure under regulation 13(1) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Leman Diversified Fund has submitted to the Exchange, vide letter dated April 15, 2014 a copy of disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 along with a copy of Disclosure under Regulation 13(1) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

News Verification : The media had reports that Dr. Datson's Labs Limited "Videocon set to acquire Datsons Labs for Rs. 350 crores". The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Dr. Datson's Labs Limited has vide its letter inter-alia stated,"We are not aware of the source for the information appearing in Business standard & deny the news item. We once again reiterate that news article is based on speculation and company has not

Davos International Fund has submitted to the Exchange, vide letter dated April 15, 2014 a copy of disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 along with a copy of Disclosure under Regulation 13(1) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Sparrow Asia Diversified Opportunities Fund has submitted to the Exchange, vide letter dated April 15, 2014 a copy of disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 along with a copy of Disclosure under Regulation 13(1) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Religare Finvest Limited has submitted to the Exchange vide letter dated April 11 , 2014 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Dr. Datson's Labs Limited has informed the Exchange that Mr. Chandulal Champaklal Shah, Chairman Emeritus of the Company, has tendered his resignation from the Chairman Emeritus of the Company with effect from April 05, 2014.

Kuvera Fund Limited has submitted to the Exchange vide letter dated March 26, 2014 a copy of disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 along with a copy of Disclosure under Regulation 13(1) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Dr. Datson's Labs Limited has informed the Exchange regarding the Outcome of the meeting of the Board of Directors of the Company held on March 18, 2014.